Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on August 13, 2018. The report addresses corporate governance changes effective as of August 8, 2018. The company is identified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of Santo "Sandy" Costa as the new Chairman of the Board of Directors. Douglas Bratton, the outgoing Chairman, will continue to serve as a member of the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the leadership transition.
Key Facts for Investor Verification
- Santo "Sandy" Costa was appointed Chairman of the Board effective August 8, 2018.
- Douglas Bratton remains on the Board of Directors following his departure as Chairman.
- The company is classified as an emerging growth company.
- No financial performance data is included in this specific filing.